HHGC
BHVN

Hunting Hill Global Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Hunting Hill Global Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,225
Closed -$324K – 122
2022
Q2 		$324K Buy
+2,225
New +$284K 0.3% 44

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hunting Hill Global Capital's BHVN Position: Q3 2022 in Review

Hunting Hill Global Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 2,225 shares — an estimated $324K sold.

Hunting Hill Global Capital first reported a position in BHVN in Q2 2022 and held it in 1 quarter. The position peaked at $324K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Hunting Hill Global Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Hunting Hill Global Capital sold 2,225 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $324K.
  • Hunting Hill Global Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 1 quarter.
  • Hunting Hill Global Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $324K in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Hunting Hill Global Capital's 13F filing for Q3 2022, filed 14 Nov 2022.